查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1386212

全球顱咽瘤治療市場：趨勢、預測與競爭分析（~2030 年）

Craniopharyngioma Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

顱咽瘤治療的趨勢與預測

預計2030年，全球顱咽瘤治療市場規模將達到約2,000萬美元，2024年至2030年年複合成長率為7.1%。該市場的主要驅動力是全球腦腫瘤盛行率的不斷上升、醫療保健支出的增加以及影像技術、放射線治療和手術技術的不斷進步。全球顱咽瘤治療市場的未來前景廣闊，醫院、診所、門診手術中心、癌症研究機構和診斷實驗室市場都有機會。

顱咽瘤治療市場洞察

Lucintel 預測，由於磁振造影(MRI) 能夠創建大腦和腦下垂體的詳細圖像，因此在預測期內將繼續成為最大的細分市場。

在這個市場中，由於醫院提供的設施、高技能的醫療保健專業人員以及尖端醫療技術的存在，醫院可能仍然是最大的細分市場。

由於該地區顱咽瘤盛行率不斷上升、先進的醫療基礎設施以及有利的報銷政策，北美在預測期內可能仍是最大的市場。

市場規模/估計：以金額的顱咽瘤治療市場規模估計（10億美元）

趨勢和預測分析：各細分市場和地區的市場趨勢（2018-2023）和預測（2024-2030）

細分分析：按診斷、治療、最終用途行業和地區分類的顱咽瘤治療市場規模估計金額（十億美元）

區域分析：北美、歐洲、亞太地區和世界其他地區顱咽瘤治療市場細分

成長機會：顱咽瘤治療市場中診斷、治療、最終用途產業和地區的成長機會分析

策略分析：顱咽瘤治療市場併購、新產品開發、競爭形勢等

基於波特五力模型的產業競爭實力分析

本報告回答了 11 個關鍵問題：

  • Q.1. 細分市場中最有前途和高成長的機會是什麼？
  • Q.2.哪個細分市場將以更快的速度成長？為什麼？
  • Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要因素有哪些？市場的主要挑戰和商業風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球顱咽瘤治療市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢與預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球顱咽瘤治療市場趨勢（2018-2023）與預測（2024-2030）
  • 全球顱咽瘤治療市場：依診斷分類
    • 磁振造影(MRI)
    • 電腦斷層掃描 (CT)
    • 切片檢查
    • 驗血
    • 荷爾蒙測試
  • 全球顱咽瘤治療市場：依治療分類
    • 外科手術
    • 放射治療
    • 化療
    • 標靶治療
    • 荷爾蒙替代療法
  • 全球顱咽瘤治療市場：依最終用途產業
    • 醫院
    • 診所
    • 門診手術中心
    • 癌症研究
    • 診斷實驗室
    • 其他

第4章 市場趨勢與預測分析：按地區（2018-2030）

  • 全球顱咽瘤治療市場：按地區
  • 北美顱咽瘤治療市場
  • 歐洲顱咽瘤治療市場
  • 亞太地區顱咽瘤治療市場
  • 其他地區顱咽瘤治療市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球顱咽瘤治療市場診斷成長機會
    • 全球顱咽瘤治療市場的成長機會（依治療）
    • 全球顱咽瘤治療市場最終用途產業的成長機會
    • 全球顱咽瘤治療市場按地區成長機會
  • 全球顱咽瘤治療市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球顱咽瘤治療市場的產能
    • 全球顱咽瘤治療市場的合併、收購與合資企業
    • 認證和許可

第7章 主要企業概況

  • Pfizer
  • Novartis
  • Merck
  • Kazia Therapeutics
  • AbbVie
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Ipsen Biopharmaceuticals
  • Johnson & Johnson
簡介目錄

Craniopharyngioma Treatment Trends and Forecast

The future of the global craniopharyngioma treatment market looks promising with opportunities in the hospital, clinic, ambulatory surgical center, cancer research institute, and diagnostic laboratory markets. The global craniopharyngioma treatment market is expected to reach an estimated $0.02 billion by 2030 with a CAGR of 7.1% from 2024 to 2030. The major drivers for this market are the increasing incidence of brain cancer across the globe, growing healthcare expenditure, and on-going advancement in imaging technology, radiation therapy, and surgical techniques.

A more than 150-page report is developed to help in your business decisions.

Craniopharyngioma Treatment by Segment

The study includes a forecast for the global craniopharyngioma treatment by diagnosis, treatment, end use industry, and region.

Craniopharyngioma Treatment Market by Diagnosis [Shipment Analysis by Value from 2018 to 2030]:

  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT)
  • Biopsy
  • Biopsy
  • Hormone Tests

Craniopharyngioma Treatment Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Targeted Therapy
  • Hormone Replacement Therapy

Craniopharyngioma Treatment Market by End Use Industry [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Cancer Research Institutes
  • Diagnostic Laboratories
  • Others

Craniopharyngioma Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Craniopharyngioma Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies craniopharyngioma treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the craniopharyngioma treatment companies profiled in this report include-

  • Pfizer
  • Novartis
  • Merck
  • Kazia Therapeutics
  • Abbvie
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Ipsen Biopharmaceuticals
  • Johnson & Johnson

Craniopharyngioma Treatment Market Insights

Lucintel forecasts that magnetic resonance imaging (MRI) will remain the largest segment over the forecast period due to its ability to develop detailed images of the brain and pituitary gland.

Within this market, hospital will remain the largest segment due to the facilities provided by hospitals, availability of highly skilled healthcare professionals, and presence of cutting-edge medical technology.

North America will remain the largest segment over the forecast period due to the increasing prevalence of craniopharyngioma, presence of advanced healthcare infrastructure, and favorable reimbursement policies in the region.

Features of the Global Craniopharyngioma Treatment Market

Market Size Estimates: Craniopharyngioma treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Craniopharyngioma treatment market size by diagnosis, treatment, end use industry, and region in terms of value ($B).

Regional Analysis: Craniopharyngioma treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different diagnosis, treatment, end use industries, and regions for the craniopharyngioma treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the craniopharyngioma treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the craniopharyngioma treatment market size?

Answer: The global craniopharyngioma treatment market is expected to reach an estimated $0.02 billion by 2030.

Q.2 What is the growth forecast for craniopharyngioma treatment market?

Answer: The global craniopharyngioma treatment market is expected to grow with a CAGR of 7.1% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the craniopharyngioma treatment market?

Answer: The major drivers for this market are the increasing incidence of brain cancer across the globe, growing healthcare expenditure, and on-going advancement in imaging technology, radiation therapy, and surgical techniques.

Q4. What are the major segments for craniopharyngioma treatment market?

Answer: The future of the craniopharyngioma treatment market looks promising with opportunities in the hospital, clinic, ambulatory surgical center, cancer research institute, and diagnostic laboratory markets.

Q5. Who are the key craniopharyngioma treatment market companies?

Answer: Some of the key craniopharyngioma treatment companies are as follows:

  • Pfizer
  • Novartis
  • Merck
  • Kazia Therapeutics
  • AbbVie
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Ipsen Biopharmaceuticals
  • Johnson & Johnson

Q6. Which craniopharyngioma treatment market segment will be the largest in future?

Answer: Lucintel forecasts that magnetic resonance imaging (MRI) will remain the largest segment over the forecast period due to its ability to develop detailed images of the brain and pituitary gland.

Q7. In craniopharyngioma treatment market, which region is expected to be the largest in next 5 years?

Answer:North America will remain the largest segment over the forecast period due to the increasing prevalence of craniopharyngioma, presence of advanced healthcare infrastructure, and favorable reimbursement policies in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the craniopharyngioma treatment market by diagnosis (magnetic resonance imaging (MRI), computed tomography (CT), biopsy,blood tests, and hormone tests), treatment (surgery, radiation therapy, chemotherapy, targeted therapy, and hormone replacement therapy), end use industry (hospitals, clinics, ambulatory surgical centers, cancer research institutes, diagnostic laboratories, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Craniopharyngioma Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Craniopharyngioma Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Craniopharyngioma Treatment Market by Diagnosis
    • 3.3.1: Magnetic Resonance Imaging (MRI)
    • 3.3.2: Computed Tomography (CT)
    • 3.3.3: Biopsy
    • 3.3.4: Blood Tests
    • 3.3.5: Hormone Tests
  • 3.4: Global Craniopharyngioma Treatment Market by Treatment
    • 3.4.1: Surgery
    • 3.4.2: Radiation Therapy
    • 3.4.3: Chemotherapy
    • 3.4.4: Targeted Therapy
    • 3.4.5: Hormone Replacement Therapy
  • 3.5: Global Craniopharyngioma Treatment Market by End Use Industry
    • 3.5.1: Hospitals
    • 3.5.2: Clinics
    • 3.5.3: Ambulatory Surgical Centers
    • 3.5.4: Cancer Research Institutes
    • 3.5.5: Diagnostic Laboratories
    • 3.5.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Craniopharyngioma Treatment Market by Region
  • 4.2: North American Craniopharyngioma Treatment Market
    • 4.2.2: North American Craniopharyngioma Treatment Market by End Use Industry: Hospitals, Clinics, Ambulatory Surgical Centers, Cancer Research Institutes, Diagnostic Laboratories, and Others
  • 4.3: European Craniopharyngioma Treatment Market
    • 4.3.1: European Craniopharyngioma Treatment Market by Diagnosis: Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Biopsy, Blood Tests, and Hormone Tests
    • 4.3.2: European Craniopharyngioma Treatment Market by End Use Industry: Hospitals, Clinics, Ambulatory Surgical Centers, Cancer Research Institutes, Diagnostic Laboratories, and Others
  • 4.4: APAC Craniopharyngioma Treatment Market
    • 4.4.1: APAC Craniopharyngioma Treatment Market by Diagnosis: Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Biopsy, Blood Tests, and Hormone Tests
    • 4.4.2: APAC Craniopharyngioma Treatment Market by End Use Industry: Hospitals, Clinics, Ambulatory Surgical Centers, Cancer Research Institutes, Diagnostic Laboratories, and Others
  • 4.5: ROW Craniopharyngioma Treatment Market
    • 4.5.1: ROW Craniopharyngioma Treatment Market by Diagnosis: Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Biopsy, Blood Tests, and Hormone Tests
    • 4.5.2: ROW Craniopharyngioma Treatment Market by End Use Industry: Hospitals, Clinics, Ambulatory Surgical Centers, Cancer Research Institutes, Diagnostic Laboratories, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Craniopharyngioma Treatment Market by Diagnosis
    • 6.1.2: Growth Opportunities for the Global Craniopharyngioma Treatment Market by Treatment
    • 6.1.3: Growth Opportunities for the Global Craniopharyngioma Treatment Market by End Use Industry
    • 6.1.4: Growth Opportunities for the Global Craniopharyngioma Treatment Market by Region
  • 6.2: Emerging Trends in the Global Craniopharyngioma Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Craniopharyngioma Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Craniopharyngioma Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Pfizer
  • 7.2: Novartis
  • 7.3: Merck
  • 7.4: Kazia Therapeutics
  • 7.5: AbbVie
  • 7.6: Bristol-Myers Squibb
  • 7.7: F. Hoffmann-La Roche
  • 7.8: Ipsen Biopharmaceuticals
  • 7.9: Johnson & Johnson